AMAG Pharmaceuticals Inc., of Lexington, Mass., named Gary J. Zieziula executive vice president and chief commercial officer...Synexus, of Manchester, UK, appointed Helena Sigal country manager for Germany and Radoslaw Janiak country manager for Poland...Vivus Inc., of Mountain View, Calif., named Michael P. Miller senior vice president and chief commercial officer

Allegro Diagnostics, of Boston, appointed Duncan Whitney vice president of research and development...Qiagen NV, of Venlo, the Netherlands, appointed Pia Garguilo and Richard Watts to its pharma business development team...Renhuang Pharmaceuticals Inc., of Harbin, China, appointed Changxiong Sun and Bingchun Wu to its board of directors as independent directors

Xcellerex Inc., of Marlborough, Mass., appointed Guy Broadbent president and CEO...The firm's former president and CEO, Joseph Zakrzewski, will remain on with the company as chairman of the board...Silicon Kinetics Inc., of San Diego, named Rick Brown and Eric Topol to its board

AcelRx Pharmaceuticals Inc., of Redwood City, Calif., has appointed Richard King president and CEO...Previously, King was president and general manager of Tercica Inc., which was acquired by Ipsen SA, of Paris, in 2008...Oxigene Inc., of South San Francisco, appointed Tamar Howson and its CEO Peter J. Langecker, to its board of directors

Semprus BioSciences Inc, of Cambridge, Mass., appointed Colin R. Gardner and Michael J. Cima to its scientific advisory board...Spectral Diagnostics Inc., of Toronto, appointed Kevin Giese and Laine Woollard to its board...TrovaGene Inc., of San Diego, named Andreas Braun vice president and chief medical officer

Arlen, who initially had joined the firm in July 2008 as president and chief medical officer, spent 11 years at the National Cancer Institute before joining Neogenix...IBio Inc., of Newark, Del., appointed Philip K. Russell to its board and named Vidadi Yusibov chief scientific officer

De Souza was previously president and CEO of Synaptic Pharmaceuticals, president and CEO of Archemix Corp., co-founder and chief scientific officer of Neurocrine Biosciences, senior vice president at Aventis and director of CNS diseases research at DuPont Merck

No CEO replacement was named, but the firm said Mel Bridges and John Chiplin both will move to executive director roles within the company...Karo Bio AB, of Stockholm, Sweden, appointed Fredrik Lindgren as CEO and president, succeeding Per Olof Wallström, who has resigned and is leaving the company

Catalyst Biosciences Inc., of South San Francisco, named William J. Dawson chief financial officer. Garnet BioTherapeutics Inc., of Malvern, Pa., appointed Sanjay Batra senior vice president of development. NeoStem Inc., of New York, appointed Mariusz Ratajczak to its scientific advisory board. Orexigen Therapeutics Inc., of San Diego, appointed Peter K. Honig to its board. PharmaNet Development Group Inc., of Princeton, N.J., named George A. McMillan chief financial officer. Transdel

AspenBio Pharma Inc., of Castle Rock, Colo., has appointed Steve Lundy CEO and a member of its board...IGEN Networks Corp., of Las Vegas, appointed Monty Ormsby president and Michael Grudman chief financial officer and secretary

CEO Appointments: Action Pharma, of Holte, Denmark, has appointed Ingelise Saunders as CEO...Before joining Action she was president and CEO of ACE BioSciences for five years, and prior to that was CEO of Celltech Pharmaceuticals Plc...as vice president of worldwide licensing and external research and vice president of basic research

to vice president of financing and administration...Pepscan Therapeutics, of Lelystad, the Netherlands, named Peter Timmerman chief technology officer and appointed Klaus Schwamborn chief development officer

IPierian Inc., of South San Francisco, appointed Michael C. Venuti president and chief scientific officer...King Pharmaceuticals Inc., of Bristol, Tenn., appointed Kevin S. Crutchfield and Derace Lan Schaffer to its board...Onyx Pharmaceuticals Inc., of Emeryville, Calif., appointed Ted W. Love executive vice president and head of R&D

VaxInnate Corp., of Cranbury, N.J., named Thomas Hofstaetter president and CEO, and Alan Shaw, who previously held that position, has assumed the newly created role of chief scientific officer and becomes board chairman

Cephalon Inc., of Frazer, Pa., promoted Kevin Buchi to chief operating officer, Wilco Groenhuysen to executive vice president and chief financial officer and Alain Aragues to executive vice president of Cephalon Europe

Tom Amick will serve as president and CEO, while Edward L. Field was named executive vice president and chief business officer...Banyan Biomarkers Inc., of Alachua, Fla., appointed Jackson Streeter CEO and chief medical officer

BIND Biosciences Inc., of Cambridge, Mass., appointed Scott Minick president and CEO...Cel-Sci Corp., of Vienna, Va., appointed Todd S. Burkhart vice president of manufacturing/facilities and commercial operations...CrystalGenomics Inc., of Seoul, South Korea, and CG Pharmaceuticals Inc., of Emeryville, Calif., appointed Eric M. Nelson vice president of business development

Senesco Technologies Inc., of New Brunswick, N.J., appointed Jack Van Hulst president and CEO...Siriuis Genomics, of Vancouver, British Columbia, appointed Chris Wagner president and CEO...UCB SA, of Brussels, Belgium, named Ismail Kola executive vice president of UCB and president of UCB New Medicines

Anesiva Inc., of South San Francisco, named Ted W. Love and David C. U'Prichard to its board, following completion of the merger with Arcion Therapeutics...CellCyte Genetics Corp., of Eastgate, Wash., appointed Douglas Cerretti chief science officer and director of business development...It also appointed Andrew K. W. Powell executive vice president, general counsel and secretary